[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100427499":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":72,"collaborators":26,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":26,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Odense University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients prophylatic treated with ABU","EXPERIMENTAL","Patients with prophylactic bladder flushing with an ABU strain.",[13],"Biological: ABU bladder lavage",{"label":15,"type":16,"description":17,"interventionNames":18},"Patients control group","PLACEBO_COMPARATOR","The control group with bladder flushing with saline solution.",[19],"Biological: Saline bladder lavage",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","ABU bladder lavage","Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Saline bladder lavage","Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline",[15],[32],{"name":33,"affiliation":34,"role":35},"Karin Andersen","University of Southern Denmark","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Karin Andersen, MD","CONTACT","+45 21570468","karin.andersen@rsyd.dk",{"name":43,"role":39,"phone":26,"phoneExt":26,"email":44},"Lars Lund, Prof.","lars.lund@rsyd.dk",[46,62],{"facility":47,"status":48,"city":49,"state":26,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Aarhus University Hospital","RECRUITING","Aarhus N","8200","Denmark","DK",{"type":54,"coordinates":55},"Point",[56,57],10.17317,56.20367,{"lat":57,"lon":56},[60],{"name":61,"role":39,"phone":40,"phoneExt":26,"email":41},"Karin U Andersen",{"facility":5,"status":48,"city":63,"state":26,"zip":64,"country":51,"countryCode":52,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Odense C","5000",{"type":54,"coordinates":66},[67,68],10.39538,55.40841,{"lat":68,"lon":67},[71],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},{"type":35,"investigatorFullName":33,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"MD","100427499","bacterial-interference-for-preventing-recurrent-urinary-tract-infection---new-ways-of-treatment-100427499",false,"NCT04846803","Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment","BIrUTI","Inclusion Criteria:\n\n* Diagnosed with recurrent cystitis including 2 times of rUTI within the last 6 months or 3 times in the last 12 months, where at least 2 cultures show the same bacteria.\n* Normal investigation for lower urinary tract diseases (LUTD) including voiding diary, symptom scores, flexible cystoscopy, voiding diagram and test for residual urine.\n* Failed previously treatments.\n* Patients with native bladder with both spontaneous voiding, the need for clean intermittent catheter (CIC) or indwelling catheter.\n* Patients with neurogenic and non-neurogenic bladder dysfunction.\n* Patients with urostomy, kidney transplantation or another complicated genesis.\n* Written consent.\n\nExclusion Criteria:\n\n* Malignancy in the urinary tract, kidney-, ureteral- or bladder stones, age \\\u003C 18 years, pregnancy, breastfeeding. Patients in ongoing orally antibiotic treatment. Not able to speak or understand Danish.",true,"ALL","18 Years","90 Years",{"count":86,"type":87},80,"ESTIMATED","INTERVENTIONAL",[90],"NA","Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It affects 150 million people annually. Treatment of patients with UTI entails a high consumption of antibiotics and large social and health costs. With this protocol, we want to elucidate alternative treatment methods for especially recurrent urinary tract infection. Bacteria have internal competitiveness (bacterial interference) and it is known that the non-pathogenic E.coli can outcompete the pathogenic E.coli in laboratory studies.\n\nWe intend to strengthen the clinical evidence that it can be used as patient treatment through a clinical, placebo-controlled, double-blind trial at Odense University Hospital.",[93],"Recurrent Urinary Tract Infections",[95,96,97,98],"rUTI","E.coli","prophylactic","bladder lavage","2025-09-14",{"date":101,"type":102},"2025-09-18","ACTUAL",{"date":104,"type":102},"2024-01-09",{"date":106,"type":87},"2027-12-01",{"name":5,"class":6},2]